Effects of Impaired Renal Function on Raltitrexed Pharmacokinetics
Author Information
Author(s): I Judson, T Maughan, P Beale, J Primrose, P Hoskin, J Hanwell, C Berry, M Walker, F Sutcliffe
Primary Institution: Institute of Cancer Research
Hypothesis
How does mild to moderate renal impairment affect the pharmacokinetics of raltitrexed?
Conclusion
Renal impairment significantly affects the pharmacokinetics of raltitrexed, leading to increased drug accumulation and longer elimination half-life.
Supporting Evidence
- The AUCs were greater for patients with renal impairment than for those with normal renal function.
- Terminal half-life was longer for the renally impaired patients.
- Adverse events were more frequent in the group with renal impairment.
Takeaway
If your kidneys don't work well, a cancer drug called raltitrexed stays in your body longer, which can be a problem.
Methodology
This was an open-label, non-randomized, parallel-group trial comparing pharmacokinetics in patients with mild to moderate renal impairment and those with normal renal function after a single intravenous dose of raltitrexed.
Potential Biases
The unequal distribution of gender in the study groups could introduce bias in the results.
Limitations
The study had an imbalance in the number of men and women in the two groups, which may confound the results.
Participant Demographics
16 adult patients with advanced solid tumors; 8 with mild to moderate renal impairment (7 women) and 8 with normal renal function (7 men).
Statistical Information
P-Value
0.002 and 0.008 for AUCs; 0.030 for terminal half-life.
Confidence Interval
95% CI 1.36-2.84 for AUCo; 1.25-3.29 for AUCo_
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website